BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 30296188)

  • 21. CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia.
    Chen R; Song XT; Chen B
    Discov Med; 2015 Oct; 20(110):185-90. PubMed ID: 26562471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.
    Jacoby E; Bielorai B; Avigdor A; Itzhaki O; Hutt D; Nussboim V; Meir A; Kubi A; Levy M; Zikich D; Zeltzer LA; Brezinger K; Schachter J; Nagler A; Besser MJ; Toren A
    Am J Hematol; 2018 Dec; 93(12):1485-1492. PubMed ID: 30187944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
    Gupta S; Kohorst M; Alkhateeb HB
    Eur J Haematol; 2024 Jan; 112(1):51-63. PubMed ID: 38105391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation.
    Schubert ML; Hückelhoven A; Hoffmann JM; Schmitt A; Wuchter P; Sellner L; Hofmann S; Ho AD; Dreger P; Schmitt M
    Hum Gene Ther; 2016 Oct; 27(10):758-771. PubMed ID: 27479233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bispecific CAR T-cells for B-cell Malignancies.
    Furqan F; Shah NN
    Expert Opin Biol Ther; 2022 Aug; 22(8):1005-1015. PubMed ID: 35653589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric antigen receptor T cells for acute lymphoblastic leukemia.
    Frey NV
    Am J Hematol; 2019 May; 94(S1):S24-S27. PubMed ID: 30784101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia.
    O'Leary MC; Lu X; Huang Y; Lin X; Mahmood I; Przepiorka D; Gavin D; Lee S; Liu K; George B; Bryan W; Theoret MR; Pazdur R
    Clin Cancer Res; 2019 Feb; 25(4):1142-1146. PubMed ID: 30309857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
    Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
    Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of CD19-directed CAR T-Cell Therapy in an Infant With Refractory Acute Lymphoblastic Leukemia.
    Breese EH; Krupski C; Nelson AS; Perentesis JP; Phillips CL
    J Pediatr Hematol Oncol; 2021 May; 43(4):152-154. PubMed ID: 32496443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice.
    Dushenkov A; Jungsuwadee P
    J Oncol Pharm Pract; 2019 Jul; 25(5):1217-1225. PubMed ID: 30890066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel.
    Ravich JW; Huang S; Zhou Y; Brown P; Pui CH; Inaba H; Cheng C; Gottschalk S; Triplett BM; Bonifant CL; Talleur AC
    Transplant Cell Ther; 2022 Feb; 28(2):73.e1-73.e9. PubMed ID: 34875402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].
    Beauvais D; Bachy E; Baruchel A; Bay JO; Caillot D; Cartron G; Damaj G; Furst S; Le Gouill S; Morschhauser F; Rabian F; Rubio MT; Thieblemont C; Yakoub-Agha I
    Bull Cancer; 2021; 108(7-8):725-729. PubMed ID: 33423776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.
    Mueller KT; Waldron E; Grupp SA; Levine JE; Laetsch TW; Pulsipher MA; Boyer MW; August KJ; Hamilton J; Awasthi R; Stein AM; Sickert D; Chakraborty A; Levine BL; June CH; Tomassian L; Shah SS; Leung M; Taran T; Wood PA; Maude SL
    Clin Cancer Res; 2018 Dec; 24(24):6175-6184. PubMed ID: 30190371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.
    Leahy AB; Elgarten CW; Grupp SA; Maude SL; Teachey DT
    Expert Rev Anticancer Ther; 2018 Oct; 18(10):959-971. PubMed ID: 30111196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas.
    Ahmad A; Uddin S; Steinhoff M
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD19 CAR Therapy for Acute Lymphoblastic Leukemia.
    Sadelain M; Brentjens R; Rivière I; Park J
    Am Soc Clin Oncol Educ Book; 2015; ():e360-3. PubMed ID: 25993197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.
    Shahid S; Ramaswamy K; Flynn J; Mauguen A; Perica K; Park JH; Forlenza CJ; Shukla NN; Steinherz PG; Margossian SP; Boelens JJ; Kernan NA; Curran KJ
    Transplant Cell Ther; 2022 Feb; 28(2):72.e1-72.e8. PubMed ID: 34852305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kymriah® (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy.
    Awasthi R; Maier HJ; Zhang J; Lim S
    Hum Vaccin Immunother; 2023 Dec; 19(1):2210046. PubMed ID: 37185251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
    Li HH; Zhu P; Wu XQ; Liu YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.